Pankaine Spinal Tung (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine hydrochloride, the active ingredient in Pankaine Spinal Tung, is a long‑acting amide local anaesthetic presented as a sterile solution for intrathecal use. It provides surgical anesthesia and postoperative analgesia, primarily in adult patients undergoing spinal or epidural procedures. GNH USA supplies Pankaine Spinal Tung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Pankaine Spinal Tung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Bupivacaine hydrochloride is employed in regional anaesthesia techniques that target the spinal and epidural spaces.

- Surgical anesthesia for lower abdominal, pelvic and lower‑limb procedures: Provides dense sensory block for the duration of surgery. - Post‑operative pain control after cesarean section: Extends analgesia into the early recovery period. - Chronic pain management via epidural infusion: Delivers continuous analgesia for refractory pain conditions. - Diagnostic spinal procedures: Facilitates patient comfort during lumbar puncture or myelography. - Labor analgesia: Offers effective pain relief during the first stage of labor.

Bupivacaine may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Hypotension: Transient drop in blood pressure following sympathetic blockade. - Bradycardia: Reduced heart rate due to vagal stimulation. - Nausea: Mild to moderate nausea during or after the procedure. - Pruritus: Itching, often associated with opioid adjuncts. - Urinary retention: Difficulty voiding after spinal block.

Serious or Rare Side Effects: - Cardiac toxicity: Arrhythmias or cardiac arrest with high plasma concentrations. - Central nervous system toxicity: Seizures, tinnitus, or metallic taste. - Allergic reaction: Rash, urticaria, or anaphylaxis. - Persistent neurological deficit: Prolonged motor or sensory block beyond expected duration. - Spinal hematoma: Accumulation of blood in the epidural or subarachnoid space. - Infection at injection site: Localized erythema or abscess formation.

When using Bupivacaine for spinal anesthesia, clinicians should observe standard safety protocols and patient‑specific considerations.

- Patient assessment: Evaluate cardiovascular status and allergy history before administration. - Dose limitation: Adhere to recommended maximum dose to avoid systemic toxicity. - Monitoring: Continuous ECG, blood pressure, and oxygen saturation during the procedure. - Resuscitation readiness: Have lipid emulsion therapy and advanced cardiac life support equipment available. - Contraindications: Avoid in patients with known hypersensitivity to amide‑type local anaesthetics. - Store at ambient temperature: Keep in original container, protect from light and moisture.

Bupivacaine can interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid): - Class III anti‑arrhythmics (e.g., amiodarone): May potentiate cardiotoxic effects. - Beta‑blockers: Can exacerbate bradycardia and hypotension. - Central nervous system depressants (e.g., benzodiazepines, opioids): Increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: May enhance hypotensive response. - Diuretics: Can alter plasma protein binding, affecting free drug levels. - MAO inhibitors: Potentially increase neuro‑excitatory toxicity.